Cargando…
P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171738/ http://dx.doi.org/10.1097/01.HS9.0000936328.14674.49 |
| _version_ | 1785039486487363584 |
|---|---|
| author | Nozzoli, C. Pucillo, M. Martino, M. Giaccone, L. Rambaldi, A. Benedetti, E. Russo, D. Mordini, N. Bernasconi, P. Mangiacavalli, S. Pioltelli, P. Carluccio, P. Galieni, P. Ladetto, M. Sica, S. Isola, M. De Martino, M. Oldani, E. Degrandi, E. Biasco, A. Fanin, R. Saccardi, R. Ciceri, F. Patriarca, F. |
| author_facet | Nozzoli, C. Pucillo, M. Martino, M. Giaccone, L. Rambaldi, A. Benedetti, E. Russo, D. Mordini, N. Bernasconi, P. Mangiacavalli, S. Pioltelli, P. Carluccio, P. Galieni, P. Ladetto, M. Sica, S. Isola, M. De Martino, M. Oldani, E. Degrandi, E. Biasco, A. Fanin, R. Saccardi, R. Ciceri, F. Patriarca, F. |
| author_sort | Nozzoli, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171738 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101717382023-05-11 P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Nozzoli, C. Pucillo, M. Martino, M. Giaccone, L. Rambaldi, A. Benedetti, E. Russo, D. Mordini, N. Bernasconi, P. Mangiacavalli, S. Pioltelli, P. Carluccio, P. Galieni, P. Ladetto, M. Sica, S. Isola, M. De Martino, M. Oldani, E. Degrandi, E. Biasco, A. Fanin, R. Saccardi, R. Ciceri, F. Patriarca, F. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171738/ http://dx.doi.org/10.1097/01.HS9.0000936328.14674.49 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Nozzoli, C. Pucillo, M. Martino, M. Giaccone, L. Rambaldi, A. Benedetti, E. Russo, D. Mordini, N. Bernasconi, P. Mangiacavalli, S. Pioltelli, P. Carluccio, P. Galieni, P. Ladetto, M. Sica, S. Isola, M. De Martino, M. Oldani, E. Degrandi, E. Biasco, A. Fanin, R. Saccardi, R. Ciceri, F. Patriarca, F. P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION |
| title | P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION |
| title_full | P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION |
| title_fullStr | P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION |
| title_full_unstemmed | P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION |
| title_short | P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION |
| title_sort | p50 overall survival advantage of monoclonal antibodies based-treatments in multiple myeloma patients relapsed after allogeneic stem cell transplantation |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171738/ http://dx.doi.org/10.1097/01.HS9.0000936328.14674.49 |
| work_keys_str_mv | AT nozzolic p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT pucillom p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT martinom p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT giacconel p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT rambaldia p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT benedettie p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT russod p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT mordinin p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT bernasconip p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT mangiacavallis p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT pioltellip p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT carlucciop p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT galienip p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT ladettom p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT sicas p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT isolam p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT demartinom p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT oldanie p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT degrandie p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT biascoa p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT faninr p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT saccardir p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT cicerif p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation AT patriarcaf p50overallsurvivaladvantageofmonoclonalantibodiesbasedtreatmentsinmultiplemyelomapatientsrelapsedafterallogeneicstemcelltransplantation |